FDA Clears Brain Analysis System

Brain assessment technology company ElMindA received FDA clearance to market the BNA Analysis System, a noninvasive device that uses EEG technology and signal processing to provide glimpses of the brain at work.

The system is currently indicated for 14 to 24 year olds, and the Israeli devicemaker is doing additional tests to support a broader age range.

The BNA system uses algorithms to measure patterns of brain networks activated during specific brain processes and compares that with activity seen in healthy brains.

ElMindA has a database of over 7,000 BNA datasets of brain activity from healthy patients and those with brain-related disorders. It will help in identifying and managing disorders such as attention deficit hyperactivity disorder and concussions, the company said.

CEO Ronen Gadot said the system adds an objective layer of information to clinical symptom assessments and neurocognitive tests, providing clinicians with a comprehensive view of brain health. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.